Md Faqrul Hasan, Amanda R Campbell, Tayler J Croom-Perez, Jeremiah L Oyer, Thomas A Dieffenthaller, Liza D Robles-Carrillo, Catherine A Cash, Jonathan E Eloriaga, Sanjana Kumar, Brendan W Andersen, Meisam Naeimi Kararoudi, Brian P Tullius, Dean A Lee, Alicja J Copik. Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies.Journal for immunotherapy of cancer. 2023, 11 (12):
Alex De Caluwe, Emanuela Romano, Philip Poortmans, Andrea Gombos, Elisa Agostinetto, Guilherme Nader Marta, Zoe Denis, Stylianos Drisis, Christophe Vandekerkhove, Antoine Desmet, Catherine Philippson, Ligia Craciun, Isabelle Veys, Denis Larsimont, Marianne Paesmans, Dirk Van Gestel, Roberto Salgado, Christos Sotiriou, Martine Piccart-Gebhart, Michail Ignatiadis, Laurence Buisseret. First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.Journal for immunotherapy of cancer. 2023, 11 (12):
Manali S Phadke, Jiannong Li, Zhihua Chen, Paulo C Rodriguez, Jessica K Mandula, Lilit Karapetyan, Peter A Forsyth, Y Ann Chen, Keiran S M Smalley. Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.Journal for immunotherapy of cancer. 2023, 11 (12):
Lei Wu, Xudong Liu, Juan Lei, Nan Zhang, Huakan Zhao, Jiangang Zhang, Huan Deng, Yongsheng Li. Fibrinogen-like protein 2 promotes tumor immune suppression by regulating cholesterol metabolism in myeloid-derived suppressor cells.Journal for immunotherapy of cancer. 2023, 11 (12):
Elisa C Toffoli, Amanda A van Vliet, Henk W M Verheul, Hans J van der Vliet, Jurriaan Tuynman, Jan Spanholtz, Tanja D de Gruijl. Allogeneic NK cells induce monocyte-to-dendritic cell conversion, control tumor growth, and trigger a pro-inflammatory shift in patient-derived cultures of primary and metastatic colorectal cancer.Journal for immunotherapy of cancer. 2023, 11 (12):
Yong-Qiang Ao, Jian Gao, Chun Jin, Shuai Wang, Li-Cheng Zhang, Jie Deng, Zong-Wei Chen, Hai-Kun Wang, Jia-Hao Jiang, Jian-Yong Ding. ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3.Journal for immunotherapy of cancer. 2023, 11 (12):
Kristin M Snyder, Kate J Dixon, Zachary Davis, Martin Hosking, Geoffrey Hart, Melissa Khaw, Anders Matson, Ryan Bjordahl, Bryan Hancock, Soheila Shirinbak, Jeffrey S Miller, Bahram Valamehr, Jianming Wu, Bruce Walcheck. iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.Journal for immunotherapy of cancer. 2023, 11 (12):
Alexandra Rose Teagle, Patricia Castro-Sanchez, Rebecca J Brownlie, Nicola Logan, Simran S Kapoor, David Wright, Robert J Salmond, Rose Zamoyska. Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion.Journal for immunotherapy of cancer. 2023, 11 (12):
Matthew H G Katz, Gina R Petroni, Todd Bauer, Matthew J Reilley, Brian M Wolpin, Chee-Chee Stucky, Tanios S Bekaii-Saab, Rawad Elias, Nipun Merchant, Andressa Dias Costa, Patrick Lenehan, Victoire Cardot-Ruffino, Scott Rodig, Kathleen Pfaff, Stephanie K Dougan, Jonathan Andrew Nowak, Gauri R Varadhachary, Craig L Slingluff, Osama Rahma. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.Journal for immunotherapy of cancer. 2023, 11 (12):
Roeland Lameris, Adam Shahine, Myrthe Veth, Bart Westerman, Dale I Godfrey, David Lutje Hulsik, Patricia Brouwer, Jamie Rossjohn, Tanja D de Gruijl, Hans J van der Vliet. Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions.Journal for immunotherapy of cancer. 2023, 11 (12):